LD-2 disclosure · 3rd Quarter - Report
SAGE THERAPEUTICS
Client
- Location
- Massachusetts · United States of America
Registrant
- Description
- Pharmaceutical manufacturing
- Location
- Cambridge, Massachusetts, United States of America
Lobbying activities
2 issuesHealth Issues
Mental Health Innovation at large substances - Cares Act. Telehealth and controlled substance prescribing habits for serious mental illness. Extension of Public Health Emergency Act for telehealth. Senate drug pricing reforms under Medicare Part D. TRIPS Waiver. Fixes to the Inflation Reduction Act of 2022 (P.L.117-169). Mental Health Care - PPD screening guidelines in Momnibus bills (H.R.3305/S.1606).
LobbyistsJULIE GARNER · MARGARET MANN
TargetedSENATE · HOUSE OF REPRESENTATIVES · Centers For Medicare and Medicaid Services (CMS)
Medicare/Medicaid
Telehealth Medicare physician reimbursement. P.L.117-169 - Inflation Reduction Act of 2022 and potential fixes to the IRA. Maternal mental health legislation, like Momnibus (H.R.3305/S.1606).
LobbyistsJULIE GARNER · MARGARET MANN
TargetedSENATE · HOUSE OF REPRESENTATIVES · Centers For Medicare and Medicaid Services (CMS)